Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Francine M Ducharme Departments of Paediatrics
and of Epidemiology and Biostatistics, McGill University Health Centre,
Montreal, QC H3H 1P3, Canada
Francine.ducharme{at}muhc.mcgill.ca
Objectives:
To examine the evidence for the efficacy
and glucocorticoid sparing effect of oral anti-leukotrienes taken daily
as add-on therapy to inhaled glucocorticoids in patients with asthma.
What is already known on this topic
No systematic review of randomised controlled trials has examined the
evidence to support this treatment strategy What this study adds
Design:
Systematic review of randomised controlled trials of children and adults with asthma comparing the addition of
anti-leukotrienes or placebo to inhaled glucocorticoids.
Main outcome measures:
The rate of exacerbations of
asthma requiring rescue systemic glucocorticoids when the intervention
was compared to the same or double dose of inhaled glucocorticoids, and
the glucocorticoid sparing effect when the intervention was aimed at
tapering the glucocorticoid.
Results:
Of 376 citations, 13 were included: 12 in adult patients and one in children. The addition of licensed doses of
anti-leukotrienes to inhaled glucocorticoids resulted in a non-significant reduction in the risk of exacerbations requiring systemic steroids (two trials; relative risk 0.61, 95% confidence interval 0.36 to 1.05). No trials comparing the use of
anti-leukotrienes with double the dose of inhaled glucocorticoids could
be pooled. The use of anti-leukotrienes resulted in no overall group
difference in the lowest achieved dose of inhaled glucocorticoids
(three trials; weighted mean difference -44.43 µg/day, -147.87 to
59.02: random effect model) but was associated with a reduction in
withdrawals owing to poor asthma control (four trials; relative risk
0.56, 0.35 to 0.89).
Conclusions:
The addition of anti-leukotrienes to
inhaled glucocorticoids may modestly improve asthma control compared
with inhaled glucocorticoids alone but this strategy cannot be
recommended as a substitute for increasing the dose of inhaled
glucocorticoids. The addition of anti-leukotrienes is possibly
associated with superior asthma control after tapering of
glucocorticoids, but the glucocorticoids sparing effect cannot be
quantified at present.
Anti-leukotrienes are increasingly being used as add-on therapy to
inhaled glucocorticoids
There is a shortage of relevant trials testing anti-leukotrienes at
licensed doses as add-on therapy to inhaled glucocorticoids in
patients, particularly children
© BMJ 2002
Read all Rapid Responses